Mannkind Corp (MNKD) Stock Price Quote, News & Filings

Summary

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

Website

www.mannkindcorp.com

Location

Danbury, CT, US

Phone818 661 5000

Employees592

CEOMichael E. Castagna

Sector

Health Care

Industry

Pharmaceuticals

IPO DateJul 28, 2004

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

We are developing a dry powder inhalation (DPI) version of ralinepag. In August 2025, we exercised the option under our license and collaboration agreement with MannKind Corp. to develop ralinepag DPI utilizing the dry powder formulation technology used to manufacture Tyvaso DPI. We believe the half-life of ralinepag may support once-daily dosing of ralinepag DPI. We are currently in the process of conducting IND-enabling non-clinical studies. In …
UNITED THERAPEUTICS CorpMannkind Corp·10-Q - Quarterly report Q3·Q3 26·4 Nov
… r. Khattar also serves as Chairman of the board of directors of Cognition Therapeutics Inc., a publicly traded pharmaceutical company. He previously served as Chairman of the board of directors of scPharmaceuticals, a publicly traded pharmaceutical company acquired by MannKind Corporation. Mr. Khattar earned his degrees in Marketing with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania.
Indivior Pharmaceuticals, Inc.Mannkind Corp·8-K - Entry into a Material Definitive Agreement·Q4 26·2 Nov
… between Teofilo Raad and the Company Form 8-K (Exhibit 10.2) 01/08/24 001-36199 10.19 Bill of Sale and Assignment Agreement, dated as of May 28, 2024, by and between Pulmatrix, Inc. and MannKind Corporation Form 10-Q (Exhibit 10.4) 08/13/24 001-36199 10.20 Intellectual Property Cross License Agreement, dated as of May 28, 2024, by and between Pulmatrix, Inc. and MannKind Corporatio …
Pulmatrix, Inc.Mannkind Corp·ARS - Annual report to security holders·FY25·5 Oct
… cancer and chronic infectious disease; he also founded AlleCure Corp., of Valencia, California, a developer of allergy treatments and immune modulating therapies. In 2001, AlleCure and CTL ImmunoTherapies merged to form MannKind Corp., where Mr. Simard served as Corporate Vice President and a board member. Mr. Simard holds a degree in Biochemistry from the University of Saskatchewan and attended graduate studies in Medical Biophysics/Immunology …
XBiotech Inc.Mannkind Corp·DEF 14A - Definitive proxy statement·Q4 26·2 Oct
… rganizations. Pulmatrix has historically supported an internal research and development team and facility for their pipeline and other potential development programs, however following the closing of the transaction with MannKind Corporation (“MannKind” and such transactions, the “MannKind Transaction”) in the year ended December 31, 2024, the majority of their research and development employees were terminated and their facility lease was assign …
Pulmatrix, Inc.Mannkind Corp·424B3 - Prospectus filing (Rule 424(b)(3))·Q3 26·25 Sep
… 0% | 8.07% | 5/6/2025 | 5/8/2030 | 35,152 | | 34,978 | | 35,152 | | 0.09 | | | BioCryst Pharmaceuticals, Inc. | (4)(6)(22) | SOFR + | 4.50% | 8.57% | 1/23/2026 | 1/23/2031 | 108,539 | | 108,071 | | 107,996 | | 0.26 | | | MannKind Corp. | (4)(6)(7)(14) | SOFR + | 5.00% | 8.74% | 8/6/2025 | 8/6/2030 | 88,776 | | 86,876 | | 87,671 | | 0.21 | | | | | | | | | | | | 289,751 | | 291,079 | | 0.71 | | | Broadline Retail | | | | | | | | | | | | | | | | Pee …
Blackstone Private Credit FundMannkind Corp·10-Q - Quarterly report Q3·Q3 26·12 Nov

Key Stats

Trading

Px/Chg 1D$3.80 / -3.80%

Avg Volume6.36M

Beta0.80

Mkt Cap1.21B

FD Mkt Cap1.25B

Float

Shrs Out/Float319.39M / 303.10M

Short Float0.09%

Days to Cover4.41

Stock Repurchased$0.00

Current Valuation

EV1.60B

EV/EBITDA57.98

EV/Sales4.43

P/B-20.50

P/S3.36

FCF Yield-0.62%

ROE28.08%

ROA-2.23%

Current Ratio1.87

Estimates

P/E-50.75

Est P/E0.00

Est EPS-0.02

Est PEG0.00

Valuation

Metric	5Yr Avg	May '23	May '24	May '25	May '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	-38.20	-11.41	-99.98	48.24	-54.81	-73.03
Price / Sales	8.39	10.00	6.00	4.66	7.81	13.46
Price / Book Value	-12.67	-3.98	-4.85	-16.89	-17.13	-20.50
Price / Free Cash Flow	-72.58	-11.30	-142.99	40.55	-87.83	-161.31
ENTERPRISE VALUE METRICS
Enterprise Value	1,329.3	1,216.1	1,227.7	1,332.3	1,272.6	1,597.5
Enterprise Value / Sales	10.42	12.19	6.17	4.67	11.37	17.72
Enterprise Value / EBITDA	44.52	-21.59	81.15	17.20	-506.22	652.05
Enterprise Value / EBIT	-90.78	-19.42	115.89	19.45	-163.53	-406.29

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Dec '21	Dec '22	Dec '23	Dec '24	Dec '25
INCOME STATEMENT
Revenue	46.7%	75.4	99.8	199.0	285.5	349.0
Gross Income	67.5%	36.6	42.3	136.2	208.9	287.8
EBITDA	—	-61.1	-56.3	15.1	77.5	27.5
EBIT	—	-64.3	-62.6	10.6	68.5	15.2
Net Income	—	-80.9	-87.4	-11.9	27.6	5.9
EPS (Diluted)	—	-0.37	-0.44	-0.04	0.10	0.02
BALANCE SHEET
Cash & ST Inv	-4.3%	204.1	170.8	295.1	197.3	171.3
Total Assets	25.3%	321.2	295.3	475.2	393.8	792.2
Total Liabilities	12.3%	530.5	545.8	721.4	472.7	843.2
Total Shareholder Equity	-29.7%	-209.3	-250.5	-246.2	-78.8	-51.0
CASH FLOW
Net Operating Cash Flow	—	-61.7	-80.7	34.1	42.5	18.3
Cap Ex	-20.6%	-11.5	-7.6	-42.4	-9.7	-4.6
Free Cash Flow	—	-73.2	-88.3	-8.3	32.8	13.7

Enterprise Value Bridge

Millions USD		13 Nov '26
Price (As of 13 Nov '26)		4.13
Basic Shares		319.39
Market Cap		1,319.1
Diluted Shares		320.18
Fully Diluted Shares Outstanding		320.18
Fully Diluted Market Cap		1,322.4
+Consolidated Debt		433.5
−In-the-Money Convertible Debt		—
+Capital Leases		11.3
+Operating Leases		—
−Cash & Equivalents		-41.3
−Short-term Investments		-55.3
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-
+Pension Liabilities		—
Enterprise Value		1,711.3

Segment data

Revenue

by Products and services

Product Revenue62%
Royalty37%
Service1%

Related companies